Enhancing Orthographic Communication and Literacy Outcomes for AAC Learners

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age5-12
SponsorPenn State University

About this trial

The goal of this clinical trial is to determine whether adding Integrated Decoding and Encoding instruction to the ALLSTAR literacy program improves reading outcomes for students with significant literacy and communication needs. The study will also examine how students' reading skills change over time across instructional conditions.

The main questions it aims to answer are:

Do students who receive ALLSTAR with Integrated Decoding and Encoding instruction demonstrate greater improvements in literacy outcomes than students who receive ALLSTAR as standard care alone? How do students' literacy skills change from baseline to mid-intervention and post-intervention across the two instructional conditions? Researchers will compare two groups using a randomized controlled trial design. One group will receive 60 lessons of ALLSTAR as the standard of care (ALLSTAR-SC), and the other group will receive 60 lessons of ALLSTAR with the addition of Integrated Decoding and Encoding lessons (ALLSTAR-I\*). Literacy outcomes will be measured using repeated assessment probes at baseline (0 Lessons), after 30-40 lessons, and after 60 lessons to evaluate differences between groups and changes over time in the individuals.

Eligibility criteria

Qualifiers

Have complex communication needs and use AAC,

are ages 5-12,

per report can follow two-step directions,

symbolic communicators with at least 75 words on the CDI and mean length of utterance greater than 2

Disqualifiers

• Do not have complex communication needs / can speak and do not need AAC,

Younger than 5 or older than 12 years of age,

Can not follow two-step directions,

Are not symbolic communicators with at least 75 words on the CDI and not combining at least 2 symbols

Trial design

Treatments tested in this trial

  • ALLSTAR

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Penn State University

Lead sponsor

National Institutes of Health (NIH)

Collaborator